SPSB1

Summary

SPSB1 (splA/ryanodine receptor domain and SOCS box containing 1, HGNC:30628) is a protein-coding gene on chromosome 1p36.22, encoding SPRY domain-containing SOCS box protein 1 (Q96BD6). Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

Enables ubiquitin-like ligase-substrate adaptor activity. Involved in protein ubiquitination and ubiquitin-dependent protein catabolic process. Located in cytosol.

Source: NCBI Gene 80176 — RefSeq curated summary.

At a glance

• GWAS associations: 40
• Clinical variants (ClinVar): 27 total
• MANE Select transcript: NM_025106

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30628
Approved symbol	SPSB1
Name	splA/ryanodine receptor domain and SOCS box containing 1
Location	1p36.22
Locus type	gene with protein product
Status	Approved
Aliases	SSB-1
Ensembl gene	ENSG00000171621
Ensembl biotype	protein_coding
OMIM	611657
Entrez	80176

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000328089, ENST00000357898, ENST00000377399, ENST00000450402, ENST00000852374, ENST00000852375, ENST00000852376, ENST00000852377, ENST00000852378, ENST00000946663, ENST00000946664

RefSeq mRNA: 1 — MANE Select: NM_025106 NM_025106

CCDS: CCDS102

Canonical transcript exons

ENST00000328089 — 3 exons

Exon	Start	End
ENSE00001172204	9355743	9356585
ENSE00001341608	9367448	9369532
ENSE00001405037	9292894	9293071

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 95.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.2192 / max 285.5084, expressed in 1728 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
514	27.2192	1728

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	95.24	gold quality
descending thoracic aorta	UBERON:0002345	93.29	gold quality
thoracic aorta	UBERON:0001515	92.57	gold quality
ascending aorta	UBERON:0001496	92.56	gold quality
aorta	UBERON:0000947	92.43	gold quality
tibial artery	UBERON:0007610	92.40	gold quality
popliteal artery	UBERON:0002250	92.38	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.08	gold quality
lower esophagus	UBERON:0013473	91.04	gold quality
mucosa of stomach	UBERON:0001199	90.96	gold quality
saphenous vein	UBERON:0007318	90.93	gold quality
gall bladder	UBERON:0002110	90.26	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.03	gold quality
vena cava	UBERON:0004087	89.98	gold quality
right coronary artery	UBERON:0001625	89.82	gold quality
left coronary artery	UBERON:0001626	89.72	gold quality
coronary artery	UBERON:0001621	89.50	gold quality
omental fat pad	UBERON:0010414	89.42	gold quality
peritoneum	UBERON:0002358	89.37	gold quality
adipose tissue of abdominal region	UBERON:0007808	89.19	gold quality
gastrocnemius	UBERON:0001388	88.91	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	88.62	gold quality
esophagus	UBERON:0001043	88.57	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.45	gold quality
subcutaneous adipose tissue	UBERON:0002190	88.30	gold quality
islet of Langerhans	UBERON:0000006	87.87	gold quality
endocervix	UBERON:0000458	87.83	gold quality
muscle of leg	UBERON:0001383	87.81	gold quality
body of uterus	UBERON:0009853	87.78	gold quality
myometrium	UBERON:0001296	87.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

91 targeting SPSB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-6794-5P	99.76	66.38	1048

Literature-anchored findings (GeneRIF, showing 8)

• SSB1/2 is part of an ssDNA-binding heterotrimeric complex, SOSS which is involved in the maintenance of genome stability. (PMID:19683501)
• Findings define a novel pathway that contributes to breast cancer recurrence and provide evidence implicating SPSB proteins in cancer. (PMID:24786206)
• SPSB1 negatively regulates the TGF-beta signaling pathway through its interaction with both endogenous and overexpressed TbetaRII (and not TbetaRI) via its Spry domain. (PMID:26032413)
• EGF signaling upregulates an E3 ubiquitin (Ub) ligase adaptor, SPRY domain-containing SOCS box protein 1 (SPSB1), which recruits Elongin B/C-Cullin complexes to conjugate lysine 29-linked poly Ubiquitin chains onto hnRNP A1. (PMID:28084329)
• SPSB1 plays a key role in ovarian cancer cell survival and proliferation. The data also reveal a novel mechanism of regulating p21 stability by SPSB1. (PMID:30712944)
• Our results indicate that the paralogs Spsb1 and Spsb4, but not Spsb2 and Spsb3, can interact with and facilitate RevErbalpha ubiquitination and degradation and regulate circadian clock periodicity. (PMID:31607207)
• Cullin-5 Adaptor SPSB1 Controls NF-kappaB Activation Downstream of Multiple Signaling Pathways. (PMID:32038638)
• SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites. (PMID:32576812)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	spsb1	ENSDARG00000056515
mus_musculus	Spsb1	ENSMUSG00000039911
rattus_norvegicus	Spsb1	ENSRNOG00000017212
drosophila_melanogaster	gus	FBGN0026238
caenorhabditis_elegans		WBGENE00021596
caenorhabditis_elegans		WBGENE00021597

Paralogs (4): SPSB2 (ENSG00000111671), SPSB3 (ENSG00000162032), FBXO45 (ENSG00000174013), SPSB4 (ENSG00000175093)

Protein

Protein identifiers

SPRY domain-containing SOCS box protein 1 — Q96BD6 (reviewed: Q96BD6)

All UniProt accessions (2): A2A276, Q96BD6

UniProt curated annotations — full annotation on UniProt →

Function. Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2. Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5.

Subunit / interactions. Component of the probable ECS(SPSB1) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SPSB1. Interacts with CUL5, RNF7, ELOB and ELOC. Directly interacts with MET tyrosine kinase domain in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. When phosphorylated, interacts with RASA1 without affecting its stability. Interacts (via B30.2/SPRY domain) with PAWR; this interaction is direct and occurs in association with the Elongin BC complex. Interacts with NOS2. Interacts with EPHB2.

Subcellular location. Cytoplasm. Cytosol.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes. Essential for its ability to link NOS2 and the ECS E3 ubiquitin ligase complex components ELOC and CUL5. The B30.2/SPRY domain is involved in MET and PAWR binding.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the SPSB family.

RefSeq proteins (1): NP_079382* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050672	FBXO45-Fsn/SPSB_families	Family

Pfam: PF00622, PF07525

UniProt features (29 total): strand 15, helix 3, turn 3, domain 2, mutagenesis site 2, sequence conflict 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2JK9	X-RAY DIFFRACTION	1.79
3F2O	X-RAY DIFFRACTION	2.05

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96BD6-F1	92.17	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 31

Mutagenesis-validated functional residues (2):

Position	Phenotype
31	loss of phosphorylation.
260–263	abolishes interaction with rnf7 and cul5.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 240 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, MODULE_522, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1, OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP, FOSTER_TOLERANT_MACROPHAGE_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, ATTCTTT_MIR186, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ACTTTAT_MIR1425P, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS

GO Biological Process (3): ubiquitin-dependent protein catabolic process (GO:0006511), protein ubiquitination (GO:0016567), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161)

GO Molecular Function (2): ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), SCF ubiquitin ligase complex (GO:0019005), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Metabolism of proteins	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein ubiquitination	1
modification-dependent protein catabolic process	1
protein modification by small protein conjugation	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
enzyme-substrate adaptor activity	1
binding	1
cytoplasm	1
cullin-RING ubiquitin ligase complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

662 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPSB1	CISH	Q9NSE2	864
SPSB1	ELOB	Q15370	671
SPSB1	SPSB3	Q6PJ21	494
SPSB1	FBXO32	Q969P5	477
SPSB1	SOCS3	O14543	465
SPSB1	CCNF	P41002	413
SPSB1	SOCS2	O14508	403
SPSB1	RASA1	P20936	389
SPSB1	CUL5	Q93034	384
SPSB1	FBXO9	Q9UK97	381
SPSB1	TPX2	Q9ULW0	377
SPSB1	A0A087WY73	A0A087WY73	376
SPSB1	ASB18	Q6ZVZ8	376
SPSB1	CDC20	Q12834	373
SPSB1	AURKA	O14965	368

IntAct

73 interactions, top by confidence:

A	B	Type	Score
VWA5A	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
ADPRH	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	CASP6	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	CCK	psi-mi:“MI:0915”(physical association)	0.560
CRYAA	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	HIP1	psi-mi:“MI:0915”(physical association)	0.560
UBE2K	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	HMOX2	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	LAMP2	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	PAK1	psi-mi:“MI:0915”(physical association)	0.560
PRKN	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	PECAM1	psi-mi:“MI:0915”(physical association)	0.560
RAN	SPSB1	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	VIM	psi-mi:“MI:0915”(physical association)	0.560
SPSB1	RNF11	psi-mi:“MI:0915”(physical association)	0.560
TARDBP	SPSB1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (59): SPSB1 (Affinity Capture-Western), TGFBR2 (Affinity Capture-Western), Tgfbr2 (Affinity Capture-Western), SPSB1 (Affinity Capture-RNA), Ephb2 (Affinity Capture-Western), EPHB2 (Affinity Capture-Western), KRAS (Affinity Capture-Western), SPSB1 (Affinity Capture-Western), SPSB1 (Affinity Capture-Western), SPSB1 (Affinity Capture-Western), SPSB1 (Two-hybrid), SPSB1 (Two-hybrid), SPSB1 (Affinity Capture-MS), SPSB1 (Two-hybrid), SPSB1 (Two-hybrid)

ESM2 similar proteins: A1Z6E0, A2BHJ4, A8IU92, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, P00860, P0C2W1, P0CH38, P11926, P27117, P27119, P27120, P48455, P53041, P53042, Q0G819, Q16XV7, Q290L5, Q5BJ41, Q5E9X6, Q5VST6, Q5XH73, Q60676, Q68FK8, Q6AXU9, Q6AY17, Q6IR85, Q6NZ03, Q7M759, Q7QGL9

Diamond homologs: A1Z6E0, A8QGZ7, A8XT88, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, O88838, P0C2W1, P0CH38, Q16XV7, Q18223, Q28DT9, Q290L5, Q5E9X6, Q5M877, Q6NZ03, Q7QGL9, Q7ZXY1, Q8K3B1, Q8R5B6, Q96A44, Q96BD6, Q99619, Q9D5L7, Q9V6L9, Q3ZBA7, Q8N3Y1, Q3MHZ2, Q571F5, Q6PJ21, Q3SX45

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen processing: Ubiquitination & Proteasome degradation	5	8.4×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
ubiquitin-dependent protein catabolic process	5	11.6×	8e-03
protein stabilization	5	10.4×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1443 predictions. Top by Δscore:

Variant	Effect	Δscore
1:9367447:GCCGA:G	acceptor_gain	1.0000
1:9293067:GCGCG:G	donor_gain	0.9900
1:9293069:GCG:G	donor_gain	0.9900
1:9293072:G:GG	donor_gain	0.9900
1:9293072:GT:G	donor_loss	0.9900
1:9293073:T:G	donor_loss	0.9900
1:9355742:GGCA:G	acceptor_gain	0.9900
1:9356582:GATC:G	donor_gain	0.9900
1:9356586:G:GG	donor_gain	0.9900
1:9367444:CCA:C	acceptor_loss	0.9900
1:9367446:A:AG	acceptor_gain	0.9900
1:9367446:A:T	acceptor_loss	0.9900
1:9367446:AGCC:A	acceptor_gain	0.9900
1:9367447:G:GA	acceptor_gain	0.9900
1:9367447:GC:G	acceptor_gain	0.9900
1:9367447:GCC:G	acceptor_gain	0.9900
1:9367447:GCCG:G	acceptor_gain	0.9900
1:9346443:A:AG	acceptor_gain	0.9800
1:9346444:G:GG	acceptor_gain	0.9800
1:9355739:TTAG:T	acceptor_loss	0.9800
1:9355740:TAGGC:T	acceptor_loss	0.9800
1:9355741:A:AG	acceptor_gain	0.9800
1:9355742:G:GG	acceptor_gain	0.9800
1:9367446:AGCCG:A	acceptor_gain	0.9700
1:9293040:A:T	donor_gain	0.9500
1:9318595:G:GG	donor_gain	0.9500
1:9355742:GGC:G	acceptor_gain	0.9500
1:9356584:TC:T	donor_gain	0.9500
1:9366096:C:T	donor_gain	0.9500
1:9293827:G:GT	donor_gain	0.9400

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000106252 (1:9338034 C>T), RS1000192268 (1:9352006 C>T), RS1000222770 (1:9357392 G>A,T), RS1000281576 (1:9356700 C>T), RS1000295711 (1:9326080 A>G), RS1000328919 (1:9340067 G>A), RS1000459771 (1:9355261 G>A,C), RS1000481437 (1:9318747 C>T), RS1000526278 (1:9367484 C>T), RS1000538084 (1:9317279 A>G), RS1000545536 (1:9368932 C>G,T), RS1000561759 (1:9300421 G>A), RS1000603969 (1:9333567 G>A), RS1000665592 (1:9323153 T>A,C), RS1000669868 (1:9364256 C>T)

Disease associations

OMIM: gene MIM:611657 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

40 associations (top):

Study	Trait	p-value
GCST001476_3	Response to tocilizumab in rheumatoid arthritis	5.000000e-08
GCST001547_1	Immune response to anthrax vaccine	4.000000e-06
GCST001713_14	Dental caries	5.000000e-07
GCST004077_2	Cognitive function	1.000000e-06
GCST004253_5	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer’s disease (Alzhiemer’s diagnosis trajectory interaction)	2.000000e-06
GCST004606_171	Eosinophil count	1.000000e-10
GCST004617_49	Eosinophil percentage of granulocytes	5.000000e-11
GCST004623_143	Neutrophil percentage of granulocytes	1.000000e-11
GCST004624_197	Sum eosinophil basophil counts	1.000000e-10
GCST007096_27	Pulse pressure	4.000000e-10
GCST007099_56	Systolic blood pressure	2.000000e-06
GCST007267_167	Systolic blood pressure	2.000000e-12
GCST007269_6	Pulse pressure	5.000000e-21
GCST007798_3	Asthma	6.000000e-11
GCST007800_68	Asthma (childhood onset)	4.000000e-18
GCST008163_489	Height	1.000000e-06
GCST008839_328	Height	9.000000e-12
GCST009391_1611	Metabolite levels	8.000000e-06
GCST012226_404	Waist circumference adjusted for body mass index	2.000000e-10
GCST012227_1124	Hip circumference adjusted for BMI	3.000000e-09
GCST90002382_53	Eosinophil percentage of white cells	6.000000e-17
GCST90002382_54	Eosinophil percentage of white cells	2.000000e-22
GCST90020024_1243	A body shape index	3.000000e-08
GCST90020024_1245	A body shape index	1.000000e-08
GCST90020024_1246	A body shape index	4.000000e-08
GCST90020025_238	Waist-to-hip ratio adjusted for BMI	2.000000e-14
GCST90020025_239	Waist-to-hip ratio adjusted for BMI	9.000000e-09
GCST90020025_240	Waist-to-hip ratio adjusted for BMI	1.000000e-12
GCST90020025_241	Waist-to-hip ratio adjusted for BMI	1.000000e-11
GCST90020026_527	Hip index	7.000000e-09

EFO canonical traits (14, from GWAS)

EFO ID	Trait name
EFO:0004645	response to vaccine
EFO:0004337	intelligence
EFO:0007710	cognitive decline measurement
EFO:0004842	eosinophil count
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0005090	basophil count
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0010377	phosphatidylcholine 34:3 measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0008039	BMI-adjusted hip circumference
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, increases methylation, affects methylation	5
Cyclosporine	decreases expression, increases expression	4
sodium arsenite	decreases stability, increases expression	3
Arsenic	affects expression, decreases methylation, increases expression	3
bisphenol A	affects expression, increases methylation	2
Acetaminophen	increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tretinoin	decreases expression, increases expression	2
Valproic Acid	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
sotorasib	affects cotreatment, increases expression	1
chloroacetaldehyde	affects expression	1
hydroxyethyl methacrylate	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
beta-lapachone	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
benzo(e)pyrene	increases methylation	1
cupric chloride	increases expression	1
arsenic disulfide	increases methylation	1
dimethylarsinous acid	increases expression	1
ICG 001	increases expression	1
licochalcone B	increases expression	1
bisphenol S	affects cotreatment, increases methylation	1
NSC 689534	affects binding, increases expression	1
trametinib	affects cotreatment, increases expression	1
PCI 5002	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.